PPARG and acute myeloid leukemia: We found that the expression of PPARγ was increased in non‐M3 AML patients and activation of this receptor using pioglitazone reduced AML cell survival; shedding light on the importance of PPARγ and its ligands in the therapeutic strategies of AML.